ISSN-2155-9929
Journal of Molecular Biomarkers & Diagnosis
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Nanotechnology as a Platform for Thermal Therapy of Prostate Cancer

Wei Wang1, Guihai Chen3* and Yongping Chen2-4*
1Department of Urology, the Second People’s Hospital of Hefei, Hefei 234000, Anhui, PR China
2Department of Biomedical Engineering, Johns Hopkins University, 720 Rutland Avenue, Baltimore, Maryland 21205, USA
3Department of Neurology, the First People’s Hospital of Chenzhou, Chenzhou 423000, Hunan, PR China
4Washington Biotechnology Inc, 6200 Seaforth Street, Baltimore, Maryland 21224, USA
Corresponding Author : Yongping Chen
Department of Neurology
the First People’s Hospital of Chenzhou
Chenzhou 423000, Hunan, PR China
E-mail: yongpingchen686@gmail.com
Corresponding Author : Guihai Chen
Department of Neurology
the First People’s Hospital of Chenzhou
Chenzhou 423000, Hunan, PR China
E-mail: chenguihai1964@163.com
Received June 29, 2013; Accepted July 03, 2013; Published July 05, 2013
Citation: Wang W, Chen G, Chen Y (2013) Nanotechnology as a Platform for Thermal Therapy of Prostate Cancer. J Mol Biomark Diagn 4:e117. doi:10.4172/2155-9929.1000e117
Copyright: © 2013 Wang W, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Molecular Biomarkers & Diagnosis

Abstract

Over the past several years, there has been increasing research and clinical interest in using nanotechnology for cancer therapy. Nanoparticle provides tremendous potential for future medical therapy. Besides targeting cancer cells, delivering and releasing drugs in a regulated manner, the specificity of nanoparticles is what makes thermal therapy as attractive as a cancer therapy. In this mini review, we discuss some of the recent advances of nanotechnology for thermal therapy of prostate cancer.

Keywords
Cancer therapy; Nanoparticle; Thermal therapy; Prostate cancer
Since 2005, cancer has become the leading cause of death in individuals under age 85 in the USA [1] and Prostate cancer (PCa) is the most common non-skin cancer diagnosed in the USA [2]. It is estimated that approximately 238,590 new cases and 29,720 prostate cancerrelated deaths will occur in the United States in 2013. Prostate cancer is now the second leading cause of cancer death in men, exceeded only by lung cancer. It accounts for 28% of all male cancers and 10% of male cancer-related deaths The PSA (prostate specific antigen) test has been used for initial diagnosis of disease, and monitored for recurrence after initial therapy and for prognosis of outcomes. Diagnosis of prostate has been substantially improved with the combined use of digital rectal examination, measurement of serum PSA levels and transrectal ultrasound [3]. Nearly 90% of men with prostate cancer were diagnosed with clinically localization [4]. Therefore, an early intervention to the disease could be more appropriate for such patients.
Currently chemotherapy is a preferred modality in the treatment of prostate cancer, [5] for example; docetaxel and mitoxantrone are considered first-line chemotherapeutic options in patients with hormone-refractory prostate cancer (HRPC) [6]. But modest drug response and significant toxicity by conventional methods of administration limit their efficacy. For these issues, targeted cancer therapies offer significant therapeutic benefits over existing chemotherapy regimens since the drug is preferentially delivered to the cancer tissue. The side effects associated with chemotherapy can be minimized by targeted drug delivery. Nanoparticles have large flexibility in engineering design with sustained-release characteristics are the most promising candidates as drug delivery carriers. Over past a few years, researchers have developed different types of nanoparticles for treatment of cancer [7]. For targeting of prostate cancer, one such antigen is the prostate specific membrane antigen (PSMA) [8,9]. PSMA is a protein abundantly expressed on the surface of prostate cancer cells, metastatic disease and the hormone-refractory form. Anti-PSMA mAbs that bind the extracellular PSMA domain were used in targeting cells for prostate cancer therapy and imaging by several research groups [10-12]. Not limiting to antibody, aptamers, also known as chemical antibodies have recently been demonstrated as ideal candidates for molecular targeting applications. Many groups developed aptamers conjugated with nanoparticles for prostate cancer therapy and molecular imaging. For example, Chu et al. [13] used A9 RNA aptamer: gelonin as conjugates to target and destroy prostatespecific membrane antigen (PSMA)-positive PCa cells. Dhar et al. [14] reported the use of A10 PSMA Apt conjugation with PLGA for targeted delivery of cisplatin to prostate cancer cells. Javier et al. [15] developed aptamer-based gold nanoparticles as contrast agents for imaging of PSMA (+) prostate cancer cells.
After we mentioned the strategy of targeting for prostate cancer above, we will discuss the treatment of prostate cancer. As low-risk clinically localized disease, the treatments of prostate cancer include watchful waiting, radical prostatectomy, external beam radiation therapy (RT) and interstitial RT (brachytherapy), freezing the prostate (cryotherapy), and androgen deprivation therapy (ADT). And for prostate cancer recurrence, the patients would be offered radiation therapy, androgen deprivation therapy (ADT), thermal therapy and others. Among of these, thermal therapy was very interesting and promising for prostate cancer locally therapy.
Thermal therapy (also called hyperthermia or thermotherapy) is a type of cancer treatment in which body tissue is exposed to high temperatures (up to 113°F). Research has shown that high temperatures can be used to damage and kill cancer cells without damage to normal tissue [16]. Thermal therapy may shrink tumors by killing cancer cells and damaging proteins and structures within the cells [17]. Several methods of hyperthermia are currently under study, including local, regional, and whole-body hyperthermia. Recently, nanoparticles for local hyperthermal show tremendous promise in the safe and effective transducers for cancer therapy. Ji et al. [18] summarized carbon nanotubes as carriers for drug delivery and thermal therapies. Kennedy et al. [19] reviewed gold-nanoparticle-mediated thermal therapies. Kumar and Mohammad [20] reported magnetic nanomaterials for controlled drug delivery and hyperthermia-based therapy. Here, we highlighted three types of nanoparticles (carbon nanotubes, gold nanoparticles, and magnetic nanoparticles) for prostate cancer thermal therapy.
Carbon nanotubes (CNT) as a class of nanomaterials holds great potential for various biomedical applications including extrinsically activated hyperthermia for prostate cancer therapy. Fisher et al. [21] demonstrated the capability of multiwalled carbon nanotubes (MWNTs) coupled with laser irradiation to enhance treatment of Human prostate cancer. Ghosh et al. [22] reported DNA-encases multiwalled carbon nanotubes (MWNTs) were used to safely eradicate prostate cancer in vivo following NIR irradiation of MWNTs. Despite these promising results, the toxicity of carbon nanotubes has been an important question in nanotechnology. CNTs from manufactured and combustion sources in the environment could have adverse effects on human health [23]. From this issue, gold nanoparticles are especially appealing due to bioinertness and biocompatibility for biomedical use. For thermal therapy of prostate cancer, Stern et al. [24] used laser activated gold nanoshells for selective prostate cancer thermal ablation. Gobin et al. [25] demonstrated elective photo-thermal destruction of prostate cancer upon application of prostate-specific EphrinA1- conjugated gold nanoshells with the NIR laser irradiation. Normally, the size of gold nanoshells is more than 100 nm which is not suitable for in vivo application. Therefore, a gold nanorod is more attractive to researchers due to small size, easily surface function and with tunable plasmon resonance (SPR) in NIR region. As agents for prostate cancer therapy, Gormley et al. [26] evaluated gold nanorods conjugated with the cyclic RGD fK peptide for prostate cancer treatment. In addition, thermotherapy using magnetic nanoparticles represents another interesting area of magnetically mediated hyperthermia for prostate cancer treatment. Johannsen et al. [27] analyzed the effects of thermotherapy using magnetic nanoparticles combined with external radiation on prostate cancer and demonstrated this technique was feasible for prostate cancer treatment. Further, morbidity and quality of life were investigated during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer, the results showed interstitial heating using magnetic nanoparticles was feasible and well tolerated in patients [28]. These promising results show nanoparticlesmediated thermal therapy can be as a minimally invasive method for hyperthermia treatment of prostate cancer.
In this mini review, we collected some examples where nanoparticles were employed to induce localized heating for thermal therapy of prostate cancer. We hope that readers will find them beneficial to their works including molecular targeting.
References

Select your language of interest to view the total content in your interested language
 
Share This Article
   
 
   
 
Relevant Topics
Disc
Disc Advances in Alternative Lung Cancer Treatment
Disc Anal Cancer Diagnosis
Disc Anti-Cancer Drug
Disc Anxiety Medicine
Disc Asbestos
Disc Bioactive Compound
Disc Biology of Cancer
Disc Biomarkers in Clinical Trials
Disc Biomarkers in Oncology
Disc Bipolar Medicine
Disc Bladder Cancer Diagnosis
Disc Blood Cancer Diagnosis
Disc Bone Cancer Stages
Disc Bone Marrow Cancer Survival
Disc Bone cancer
Disc Brain Cancer Diagnosis
Disc Brain Tumor Treatment
Disc Breast Cancer Diagnosis
Disc COPD
Disc Cancer Diagnosis
Disc Cancer Progression and Diagnostics
Disc Cancer Science
Disc Cancer Therapeutics
Disc Cancer Therapies
Disc Carcinoma Case Reports
Disc Cellular Medicine
Disc Cervical Cancer Diagnosis
Disc Colon Cancer Diagnosis
Disc DNA Replication
Disc Depression Medicine
Disc Diabetic Medicine
Disc Diagnosis of Tuberculosis
Disc Diagnostic Therapeutics
Disc Disease Diagnosis
Disc Dyspnea
Disc Epigenomics
Disc Esophageal Cancer
Disc Esophageal Cancer Diagnosis
Disc Ethics in genetic engineering
Disc Evolutionary Biology
Disc Functional Genomics
Disc Gene Therapy
Disc Gene cloning
Disc Genetic Diagnosis
Disc Genetic Diagnostics
Disc Genetic Engineering in Medicine
Disc Genetic Probes
Disc Genetic Screening
Disc Genetic Testing
Disc Genetic engineering application
Disc Genetic engineering crops
Disc Genetic linkage analysis
Disc Genetically engineered animals
Disc Genetically engineering foods
Disc Genomic Medicine
Disc Genomics in Infectious Diseases
Disc Green genetic engineering
Disc Gynecological Oncology
Disc Hematology Case Reports
Disc Human Biology
Disc Human Molecular Genetics
Disc Human genetic engineering
Disc In vitro Diagnostics
Disc Insulin genetics
Disc Integrative Medicine
Disc Kidney Cancer Diagnosis
Disc Kidney Cancer Prognosis
Disc Leukemia Diagnosis
Disc Liver Cancer Case Reports
Disc Liver Cancer Diagnosis
Disc Lung
Disc Lung Cancer
Disc Lung Cancer Case Reports
Disc Lung Cancer Diagnosis
Disc Lung Cancer Facts
Disc Lung Cancer Prognosis
Disc Lung Cancer Stages
Disc Lung Cancer Survival Rate
Disc Lung Cancer Symptoms in Women
Disc Lung Cancer Treatment
Disc Lung Diseases
Disc Lung Tumor
Disc Lungs Cancer Cure
Disc Lymph Node Cancer
Disc Lymphoma Diagnosis
Disc Mass Spectrometry Based Quantitative Metabolomics
Disc Medicinal Biotechnology
Disc Mesothelioma
Disc Mesothelioma Diagnosis
Disc Metabolomics
Disc Molecular Basis of Cancer
Disc Molecular Basis of Obesity
Disc Molecular Biomarkers
Disc Molecular Diagnosis
Disc Molecular Diagnostic Market
Disc Molecular Diagnostics
Disc Molecular Forensics
Disc Molecular Genetic Test
Disc Molecular Medicine
Disc Molecular Tools for Earlier Diagnosis
Disc Mouth Cancer Diagnosis
Disc Multi Parametric Molecular Diagnostics
Disc Neoplasm
Disc Nuclear Medicine
Disc Oncogenes
Disc Oseophagus Cancer
Disc Ovarian Cancer Diagnosis
Disc Ovarian Cancer and Prognosis
Disc Oxidative Stress Biomarkers
Disc Pancreatic Cancer
Disc Pancreatic Cancer Diagnosis
Disc Pathology Diagnosis
Disc Pathology and Molecular Medicine
Disc Personalized Medicine
Disc Prostate Breast
Disc Prostate Cancer Diagnosis
Disc RFLP
Disc RNA Splicing
Disc Radiation Therapy Case Reports
Disc Recombinant DNA
Disc Rectal Cancer Diagnosis
Disc Salivary Biomarkers
Disc Sarcoma Cancer
Disc Serum Biomarkers
Disc Signs of Lung Cancer
Disc Skin Cancer
Disc Skin Cancer Diagnosis
Disc Small Cell Lung Cancer
Disc Stage 4 Lung Cancer
Disc Symptoms of Lung Cancer
Disc Testicular Cancer Diagnosis
Disc Thyroid Cancer Diagnosis
Disc Trans-Genesis
Disc Tumour Biomarkers
Disc Types of Lung Cancer
Disc Uterine Cancer Diagnosis
Disc Virus Diagnosis
 
Recommended Journals
Disc Cellular & Molecular Medicine Journal
Disc Cancer Science & Therapy Journal
Disc Oncology & Cancer Case Reports Journal
Disc Lung Cancer Diagnosis & Treatment Journal
Disc Cancer Diagnosis Journal
Disc Molecular and Genetic Medicine Journal
Disc Molecular & Genetic Medicine Journal
Disc Advances in Molecular Diagnostics Journal
Disc Biology and Medicine Journal
Disc Genetic Engineering Journal
Disc Molecular and Genetic Journal
  View More»
 
Recommended Conferences
Disc 2nd Synthetic Biology Conference
Aug 15-17, 2016 London, UK
Disc 5th Computational Systems Biology Conference
Aug 22-23, 2016 Philadelphia, USA
Disc Cancer Biomarkers Conference
Sept 15-17, 2016 Berlin, Germany
Disc 7th Biomarkers and Research Conference
Oct 31-Nov 02, 2016 Baltimore, USA
Disc Clinical and Molecular Genetics Conference
Nov 28-30, 2016 Chicago, USA
 
Article Tools
Disc Export citation
Disc Share/Blog this article
 
Article usage
  Total views: 11171
  [From(publication date):
August-2013 - May 26, 2016]
  Breakdown by view type
  HTML page views : 7444
  PDF downloads :3727
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

 
OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version